Media

Media

GBT is a biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. The company has one FDA-approved therapy for sickle cell disease and one investigational therapy in development for the disease.

Recent News

DateTitle
01/08/20GBT Announces New Employment Inducement Grants
01/07/20GBT to Present at the 38th Annual J.P. Morgan Healthcare Conference
12/18/19GBT Secures $150 Million Non-Dilutive Term Loan Financing
12/18/19GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia

More »

Media Resources


Media Contact

Steven Immergut (media)
GBT
650-410-3258
media@gbt.com